Global Blood Transfusion Diagnostics Market Size, Share, Forecast Report, 2020-2027

Global Blood Transfusion Diagnostics Market Size is expected to reach USD 2.45 billion in 2023 from USD 1.50 billion in 2016 with a CAGR of approximately 8.2% during the forecast period 2017-2023.

Intravenous transfer of blood or blood products is known as blood transfusion. Replacement of lost blood components can be done with the help of blood transfusion. Blood components like red blood cells, white blood cells, platelets, clotting factors and plasma are mostly transfused. These blood components are of great importance to laboratories and hospitals during an emergency or a critical case of large volume of blood loss. RBC transfusion is done when hemoglobin levels fall below 100g/L. Blood collected from the donor has to be screened for a number of infectious disease before transfusion. Thus, blood transfusion diagnostics play an important role in blood transfusion in order to avoid infection to both the receiver and healthcare staff. Rising prevalence of infectious diseases, increasing in number of blood transfusion procedures, demand for screened blood products and increasing campaigning or awareness programs drive the growth of this market. Demand of blood and blood products exceeds over their supply thus contributing to the growth of this market.
Segmentation:

Global Blood Transfusion Diagnostics market has been segmented on the basis of blood product including Red Blood Cells, Platelets, Plasma, Albumin, Immunoglobulin Preparations and other products. On the basis of technology, the market is segmented into Western Blot, ELISA, Nucleic Acid Amplification, Fluorescence assay, Rapid Test and other technologies. ELISA is further segmented into chemiluminescence immunoassay (CLIA), fluorescence immunoassays (FIA), and colorimetric immunoassay (CI). Nucleic Acid Amplification is segmented into Thermomechanical analysis (TMA) and real-time PCR. End users are hospitals, clinics, blood banks, laboratories.
Key Players

Grifols (Spain), Thermo Fisher Scientific, Inc. (U.S.), Roche Diagnostics (Switzerland), bioMérieux (France), Bio-Rad Laboratories, Inc. (U.S.), Immucor (U.S), Siemens Healthineers (Germany), Ortho Clinical Diagnostics, Inc. (U.S.), Becton, Dickinson and Company (U.S.), Novartis AG (Switzerland), Beckman Coulter, Inc. (U.S.), Ortho Clinical Diagnostics (U.S), Beckman Coulter (U.S), Diagast (France), Abbott Diagnostics (U.S), BAG healthcare (Germany), DiaSorin (Italy), Fujirebio (Belgium), Grifols (Spain), Quidel (U.S), Hologic/Gen-Probe (U.S), Biokit (Spain).